Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids, 7838-7840 [2022-02802]
Download as PDF
<![CDATA[
7838
Federal Register / Vol. 87, No. 28 / Thursday, February 10, 2022 / Notices
award up to $50 million in additional
universal service funding to Tribal
Areas, including Alaska, to accelerate
mobile broadband availability in these
remote and underserved areas. In its
May 2012 Third Order on
Reconsideration (FCC 12–52), the
Commission revised certain rules
adopted in the USF/ICC Transformation
Order, including the deadline by which
MF–I and TMF–I support recipients
must file their annual reports pursuant
to 47 CFR 54.1009(a). The information
being collected under this information
collection will be used by the
Commission to ensure that MF–I and
TMF–I support recipients are meeting
the public interest obligations
associated with receiving such support.
Federal Communications Commission.
Katura Jackson,
Federal Register Liaison Officer.
[FR Doc. 2022–02896 Filed 2–9–22; 8:45 am]
BILLING CODE 6712–01–P
OFFICE OF GOVERNMENT ETHICS
Agency Information Collection
Activities; Information Collection
Renewal; Comment Request for OGE
Form 319 Request for a Medical
Exception to the Covid–19 Vaccination
Requirement
AGENCY:
Office of Government Ethics
(OGE).
Notice and request for
comments.
ACTION:
After this first round notice
and public comment period, the Office
of Government Ethics (OGE) plans to
request that the Office of Management
and Budget (OMB) renew its approval
under the Paperwork Reduction Act for
an existing information collection,
entitled the OGE Form 319 Request for
a Medical Exception to the Covid–19
Vaccination Requirement. The form was
originally granted emergency clearance
on November 19, 2021.
DATES: Written comments by the public
and agencies on this proposed extension
are invited and must be received by
April 11, 2022.
ADDRESSES: Comments may be
submitted to OGE by any of the
following methods:
Email: usoge@oge.gov (Include
reference to ‘‘OGE Form 319 Request for
a Medical Exception to the Covid–19
Vaccination Requirement comment’’ in
the subject line of the message.)
Mail, Hand Delivery/Courier: Office of
Government Ethics, 1201 New York
Avenue NW, Suite 500, Attention:
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:18 Feb 09, 2022
Jkt 256001
Jennifer Matis, Associate Counsel,
Washington, DC 20005–3917.
Instructions: Comments may be
posted on OGE’s website, www.oge.gov.
Sensitive personal information, such as
account numbers or Social Security
numbers, should not be included.
Comments generally will not be edited
to remove any identifying or contact
information.
FOR FURTHER INFORMATION CONTACT:
Jennifer Matis at the U.S. Office of
Government Ethics; telephone: 202–
482–9216; TTY: 800–877–8339; Email:
jmatis@oge.gov. A copy of the form may
be obtained, without charge, by
contacting Jennifer Matis.
SUPPLEMENTARY INFORMATION:
Title: Request for a Medical Exception
to the Covid–19 Vaccination
Requirement.
Agency Form Number: OGE Form
319.
Abstract: The OGE Form 319 collects
information necessary to document the
consideration, decision, and
implementation of OGE employee
requests for reasonable accommodation
from the COVID vaccination
requirement set forth in Executive Order
14043, Requiring Coronavirus Disease
2019 Vaccination for Federal Employees
(Sept. 9, 2021).
OMB Control Number: 3209–0011.
Type of Information Collection:
Extension of a currently approved
collection.
Type of Review Request: Regular.
Affected public: Medical providers
who are asked to provide
documentation in support of an
employee’s request for a medical
exception to the requirement for
COVID–19 vaccination.
Estimated Annual Number of
Respondents: 1 (based on an estimate of
five respondents over a ten year period,
rounded up).
Estimated Time per Response: 10
minutes.
Estimated Total Annual Cost Burden
(in dollars): 17.
Request for Comments: OGE is
publishing this first round notice of its
intent to request paperwork clearance
renewal for the OGE Form 319. Public
comment is invited specifically on the
need for and practical utility of this
information collection, the accuracy of
OGE’s burden estimate, the
enhancement of quality, utility and
clarity of the information collected, and
the minimization of burden (including
the use of information technology).
Comments received in response to this
notice will be summarized for and
included with the OGE request for
extension of OMB paperwork approval.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
The comments will also become a
matter of public record.
A Notice Regarding Injunctions: The
vaccination requirement issued
pursuant to E.O. 14043 is currently the
subject of a nationwide injunction.
While that injunction remains in place,
OGE will not process requests for a
medical exception from the COVID–19
vaccination requirement pursuant to
E.O. 14043. OGE will also not request
the submission of any medical
information related to a request for an
exception from the vaccination
requirement pursuant to E.O. 14043
while the injunction remains in place.
But OGE may nevertheless receive
information regarding a medical
exception. That is because, if OGE were
to receive a request for an exception
from the COVID–19 vaccination
requirement pursuant to E.O. 14043
during the pendency of the injunction,
OGE will accept the request, hold it in
abeyance, and notify the employee who
submitted the request that
implementation and enforcement of the
COVID–19 vaccination requirement
pursuant to E.O. 14043 is currently
enjoined and that an exception therefore
is not necessary so long as the
injunction is in place. In other words,
during the pendency of the injunction,
any information collection related to
requests for medical exception from the
COVID–19 vaccination requirement
pursuant to E.O. 14043 is not
undertaken to implement or enforce the
COVID–19 vaccination requirement.
Approved: February 7, 2022.
Emory Rounds,
Director, U.S. Office of Government Ethics.
[FR Doc. 2022–02826 Filed 2–9–22; 8:45 am]
BILLING CODE 6345–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0024]
Proposed 2022 CDC Clinical Practice
Guideline for Prescribing Opioids
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) within
the Department of Health and Human
Services (HHS), announces the opening
of a docket to obtain comment on the
proposed clinical practice guideline,
CDC Clinical Practice Guideline for
SUMMARY:
E:\FR\FM\10FEN1.SGM
10FEN1
jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 28 / Thursday, February 10, 2022 / Notices
Prescribing Opioids—United States,
2022 (the clinical practice guideline).
The clinical practice guideline updates
and expands the CDC Guideline for
Prescribing Opioids for Chronic Pain—
United States, 2016, and provides
evidence-based recommendations for
clinicians who provide pain care,
including those prescribing opioids, for
outpatients age 18 years and older with
acute pain (duration less than 1 month),
subacute pain (duration of 1–3 months),
or chronic pain (duration of 3 months or
more), not including sickle cell diseaserelated pain management, cancer pain
treatment, palliative care, and end-oflife care. The clinical practice guideline
includes recommendations for primary
care clinicians (including physicians,
nurse practitioners, and physician
assistants) as well as for outpatient
clinicians in other specialties (including
those managing dental and postsurgical
pain in outpatient settings and
emergency clinicians providing pain
management for patients being
discharged from emergency
departments). This voluntary clinical
practice guideline provides
recommendations and does not require
mandatory compliance; and the clinical
practice guideline is intended to be
flexible so as to support, not supplant,
clinical judgment and individualized,
patient-centered decision-making.
DATES: Written comments must be
received on or before April 11, 2022.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2022–
0024, by either of the following
methods.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Center for Injury
Prevention and Control, Centers for
Disease Control and Prevention, 4770
Buford Highway NE, Mailstop S106–9,
Atlanta, GA 30341, Attn: Docket No.
CDC–2022–0024.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. Do not
submit comments by email. CDC does
not accept comments by email. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Arlene I. Greenspan, National Center for
Injury Prevention and Control, Centers
for Disease Control and Prevention,
4770 Buford Highway NE, MS S106–9,
Atlanta, GA 30341; Telephone: 770–
488–4696. Email: opioids@cdc.gov.
VerDate Sep<11>2014
18:18 Feb 09, 2022
Jkt 256001
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
Do not submit comments by email. CDC
does not accept comments by email.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign.
Background
In the CDC Guideline for Prescribing
Opioids for Chronic Pain—United
States, 2016, CDC communicated the
intent to evaluate and reassess evidence
and recommendations as new evidence
became available and to determine
when new evidence would prompt an
update. To achieve these aims, CDC
funded the Evidence-based Practice
Centers at the Agency for Healthcare
Research and Quality (AHRQ) to
conduct systematic reviews of the
scientific evidence in the following five
areas: (1) Noninvasive
nonpharmacological treatments for
chronic pain; (2) nonopioid
pharmacologic treatments for chronic
pain; (3) opioid treatments for chronic
pain; (4) treatments for acute pain; and
(5) acute treatments for episodic
migraine. Based upon the new evidence
described in these reviews, an update to
the CDC Guideline for Prescribing
Opioids for Chronic Pain—United
States, 2016 was warranted.
CDC developed the clinical practice
guideline using the Grading of
Recommendations, Assessment,
Development, and Evaluation (GRADE)
framework, which specifies the
systematic review of scientific evidence
and offers a transparent approach to
grading quality of evidence and strength
of recommendations. Recommendations
were made based on systematic reviews
of the available scientific evidence
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
7839
while considering benefits and harms;
patients’, caregivers’, and clinicians’
values and preferences for pain
treatment; and resource allocation (e.g.,
costs to patients or health systems,
including clinician time). CDC drafted
recommendation statements in the
clinical practice guideline focused on
assisting clinicians in determining
whether to initiate opioids for pain;
opioid selection and dosage; opioid
duration and follow-up; and assessing
risk and addressing potential harms of
opioid use.
This clinical practice guideline is
voluntary; it provides recommendations
and does not require mandatory
compliance. It is intended to be flexible
to support, not supplant, clinical
judgment and individualized, patientcentered decision-making. This clinical
practice guideline is not intended to be
applied as inflexible standards of care
across patient populations by healthcare
professionals, health systems, thirdparty payers, organizations, or
governmental jurisdictions. The clinical
practice guideline is intended to achieve
the following: Improved communication
between clinicians and patients about
the risks and benefits of pain treatment,
including opioid therapy for pain;
improved safety and effectiveness for
pain treatment, resulting in improved
function and quality of life for patients
experiencing pain; and a reduction in
the risks associated with long-term
opioid therapy, including opioid use
disorder, overdose, and death.
To help assure the clinical practice
guideline’s integrity, credibility, and
consideration of patients’, caregivers’,
and providers’ values and preferences,
CDC obtained input from patients,
caregivers, experts, clinicians, the
public, and a federally chartered
advisory committee, the Board of
Scientific Counselors of the National
Center for Injury Prevention and Control
(BSC/NCIPC). CDC is also currently
obtaining feedback from a panel of
external peer reviewers who are experts
in topic areas related to opioid
prescribing. The panel of external peer
reviewers’ feedback will be addressed
and incorporated into the final clinical
practice guideline at the same time that
public comments received in response
to this Notice are considered.
For more information about the
clinical practice guideline or the process
of updating it, please visit https://
www.cdc.gov/opioids/guideline-update/
index.html.
Supporting and Related Material in the
Docket
The docket contains the following
supporting and related materials to help
E:\FR\FM\10FEN1.SGM
10FEN1
jspears on DSK121TN23PROD with NOTICES1
7840
Federal Register / Vol. 87, No. 28 / Thursday, February 10, 2022 / Notices
inform public comment: (1) The draft
clinical practice guideline; (2) the
GRADE tables; (3) the Opioid
Workgroup (OWG) Report, prepared at
the request of the BSC/NCIPC and
which the BSC/NCIPC unanimously
voted to have CDC adopt, and CDC’s
response to observations outlined in the
OWG Report; and (4) an Overview of
Community Engagement and Public
Comment Opportunities, which
describes key themes that emerged
about stakeholders’ values and
preferences regarding pain management,
as well as CDC’s response to input
obtained from these efforts. The GRADE
tables include clinical evidence review
ratings of the evidence for the key
clinical questions. The OWG Report
describes the workgroup’s findings and
observations about the initial draft
clinical practice guideline as presented
to the BSC/NCIPC at a public meeting
on July 16, 2021. The OWG, comprising
three BSC/NCIPC members in
accordance with federal advisory
committee policy, as well as patients
with pain, caregivers, and family
members of patients with pain, and
clinicians and subject matter experts
with a variety of relevant pain
management expertise, was designed to
provide independent, broad, external,
transparent input to the BSC/NCIPC on
the diverse and complex issues
addressed in the clinical practice
guideline. OWG meetings were
coordinated by an NCIPC subject matter
expert who served as the Designated
Federal Official. CDC’s response to the
OWG Report reflects and describes how
CDC incorporated OWG observations
and comments in the revised draft of the
clinical practice guideline. The
Overview of Community Engagement
and Public Comment Opportunities
document provides a summary of efforts
implemented throughout the clinical
practice guideline update process to
better understand the lived experiences
and perspectives of community
members that we serve and to ensure
additional input from patients,
caregivers, clinicians, and the public.
CDC’s response to the themes and
findings that emerged throughout the
community engagement and public
comment opportunities describes how
CDC carefully considered and
incorporated diverse perspectives and
input from multiple sources and
stakeholders into the clinical practice
guideline.
Dated: February 7, 2022.
Angela K. Oliver,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2022–02802 Filed 2–9–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–1030]
Brenda K. Marmas: Final Debarment
Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
Brenda K. Marmas for a period of 5
years from importing or offering for
import any drug into the United States.
FDA bases this order on a finding that
Ms. Marmas engaged in a pattern of
importing or offering for import
misbranded drugs (i.e., in an amount,
frequency, or dosage that is inconsistent
with her personal or household use) that
are not designated in an authorized
electronic data interchange system as
products regulated by FDA. Ms. Marmas
was given notice of the proposed
debarment and was given an
opportunity to request a hearing to show
why she should not be debarred. As of
December 12, 2021 (30 days after receipt
of the notice), Ms. Marmas had not
responded. Ms. Marmas’ failure to
respond and request a hearing
constitutes a waiver of her right to a
hearing concerning this matter.
DATES: This order is applicable February
10, 2022.
ADDRESSES: Submit applications for
termination of debarment to the Dockets
Management Staff, Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, 240–402–
7500, or at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Enforcement
(ELEM–4029), Office of Strategic
Planning and Operational Policy, Office
of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr.,
Rockville, MD 20857, 240 402–8743, or
at debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Section 306(b)(1)(D) of the FD&C Act
(21 U.S.C. 335a(b)(1)(D)) permits
VerDate Sep<11>2014
18:18 Feb 09, 2022
Jkt 256001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
debarment of an individual from
importing or offering for import any
drug into the United States if FDA finds,
as required by section 306(b)(3)(D) of
the FD&C Act, that the individual has
engaged in a pattern of importing or
offering for import misbranded drugs
(i.e., in an amount, frequency, or dosage
that is inconsistent with personal or
household use by the importer), and the
shipments are not designated in an
entry in an authorized electronic data
exchange system as products regulated
by FDA.
After an investigation, FDA
discovered that Ms. Marmas has
engaged in numerous instances of
importing or offering for import
misbranded drugs; all the parcels
containing the misbranded drugs
serving as the basis for this action,
described in further detail below, were
intercepted by FDA at either the John F.
Kennedy International Airport (JFK),
San Francisco International Airport
(SFO), or Chicago International Airport
Mail Facilities (MF) and were addressed
to Ms. Marmas at an address connected
to her.
On or about March 3, 2020, Ms.
Marmas offered for import a parcel
intercepted and processed by FDA at
JFK MF that was addressed to her. This
parcel contained multiple products.
FDA determined that one of the
products contained in this parcel was
1,000 tablets of levofloxacin IP and was
a misbranded drug for a number of
reasons: (1) The article was determined
to be a prescription drug but did not
include the symbol ‘‘Rx only’’ on its
label; (2) the article had been
determined to lack adequate directions
for use; (3) the drug was not included
in a list required by section 510(j) of the
FD&C Act (21 U.S.C. 360(j)); and (4) the
drug was manufactured, prepared,
propagated, compounded, or processed
in an establishment not duly registered
under section 510 of the FD&C Act. FDA
also determined that another product
contained in this parcel was 900 tablets
of moxifloxacin hydrochloride and was
a misbranded drug for a number of
reasons: (1) The article was determined
to be a prescription drug but did not
include the symbol ‘‘Rx only’’ on its
label; (2) the article had been
determined to lack adequate directions
for use; (3) the drug was not included
in a list required by section 510(j) of the
FD&C Act; and (4) the drug was
manufactured, prepared, propagated,
compounded, or processed in an
establishment not duly registered under
section 510 of the FD&C Act. Both
products were refused entry on March
26, 2020.
E:\FR\FM\10FEN1.SGM
10FEN1
]]>Agencies
[Federal Register Volume 87, Number 28 (Thursday, February 10, 2022)]
[Notices]
[Pages 7838-7840]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02802]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0024]
Proposed 2022 CDC Clinical Practice Guideline for Prescribing
Opioids
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) within
the Department of Health and Human Services (HHS), announces the
opening of a docket to obtain comment on the proposed clinical practice
guideline, CDC Clinical Practice Guideline for
[[Page 7839]]
Prescribing Opioids--United States, 2022 (the clinical practice
guideline). The clinical practice guideline updates and expands the CDC
Guideline for Prescribing Opioids for Chronic Pain--United States,
2016, and provides evidence-based recommendations for clinicians who
provide pain care, including those prescribing opioids, for outpatients
age 18 years and older with acute pain (duration less than 1 month),
subacute pain (duration of 1-3 months), or chronic pain (duration of 3
months or more), not including sickle cell disease-related pain
management, cancer pain treatment, palliative care, and end-of-life
care. The clinical practice guideline includes recommendations for
primary care clinicians (including physicians, nurse practitioners, and
physician assistants) as well as for outpatient clinicians in other
specialties (including those managing dental and postsurgical pain in
outpatient settings and emergency clinicians providing pain management
for patients being discharged from emergency departments). This
voluntary clinical practice guideline provides recommendations and does
not require mandatory compliance; and the clinical practice guideline
is intended to be flexible so as to support, not supplant, clinical
judgment and individualized, patient-centered decision-making.
DATES: Written comments must be received on or before April 11, 2022.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0024, by either of the following methods.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Center for Injury Prevention and Control,
Centers for Disease Control and Prevention, 4770 Buford Highway NE,
Mailstop S106-9, Atlanta, GA 30341, Attn: Docket No. CDC-2022-0024.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to https://regulations.gov, including any personal
information provided. Do not submit comments by email. CDC does not
accept comments by email. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Arlene I. Greenspan, National Center
for Injury Prevention and Control, Centers for Disease Control and
Prevention, 4770 Buford Highway NE, MS S106-9, Atlanta, GA 30341;
Telephone: 770-488-4696. Email: [email protected].
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. Do not submit comments by email.
CDC does not accept comments by email. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign.
Background
In the CDC Guideline for Prescribing Opioids for Chronic Pain--
United States, 2016, CDC communicated the intent to evaluate and
reassess evidence and recommendations as new evidence became available
and to determine when new evidence would prompt an update. To achieve
these aims, CDC funded the Evidence-based Practice Centers at the
Agency for Healthcare Research and Quality (AHRQ) to conduct systematic
reviews of the scientific evidence in the following five areas: (1)
Noninvasive nonpharmacological treatments for chronic pain; (2)
nonopioid pharmacologic treatments for chronic pain; (3) opioid
treatments for chronic pain; (4) treatments for acute pain; and (5)
acute treatments for episodic migraine. Based upon the new evidence
described in these reviews, an update to the CDC Guideline for
Prescribing Opioids for Chronic Pain--United States, 2016 was
warranted.
CDC developed the clinical practice guideline using the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE)
framework, which specifies the systematic review of scientific evidence
and offers a transparent approach to grading quality of evidence and
strength of recommendations. Recommendations were made based on
systematic reviews of the available scientific evidence while
considering benefits and harms; patients', caregivers', and clinicians'
values and preferences for pain treatment; and resource allocation
(e.g., costs to patients or health systems, including clinician time).
CDC drafted recommendation statements in the clinical practice
guideline focused on assisting clinicians in determining whether to
initiate opioids for pain; opioid selection and dosage; opioid duration
and follow-up; and assessing risk and addressing potential harms of
opioid use.
This clinical practice guideline is voluntary; it provides
recommendations and does not require mandatory compliance. It is
intended to be flexible to support, not supplant, clinical judgment and
individualized, patient-centered decision-making. This clinical
practice guideline is not intended to be applied as inflexible
standards of care across patient populations by healthcare
professionals, health systems, third-party payers, organizations, or
governmental jurisdictions. The clinical practice guideline is intended
to achieve the following: Improved communication between clinicians and
patients about the risks and benefits of pain treatment, including
opioid therapy for pain; improved safety and effectiveness for pain
treatment, resulting in improved function and quality of life for
patients experiencing pain; and a reduction in the risks associated
with long-term opioid therapy, including opioid use disorder, overdose,
and death.
To help assure the clinical practice guideline's integrity,
credibility, and consideration of patients', caregivers', and
providers' values and preferences, CDC obtained input from patients,
caregivers, experts, clinicians, the public, and a federally chartered
advisory committee, the Board of Scientific Counselors of the National
Center for Injury Prevention and Control (BSC/NCIPC). CDC is also
currently obtaining feedback from a panel of external peer reviewers
who are experts in topic areas related to opioid prescribing. The panel
of external peer reviewers' feedback will be addressed and incorporated
into the final clinical practice guideline at the same time that public
comments received in response to this Notice are considered.
For more information about the clinical practice guideline or the
process of updating it, please visit https://www.cdc.gov/opioids/guideline-update/.
Supporting and Related Material in the Docket
The docket contains the following supporting and related materials
to help
[[Page 7840]]
inform public comment: (1) The draft clinical practice guideline; (2)
the GRADE tables; (3) the Opioid Workgroup (OWG) Report, prepared at
the request of the BSC/NCIPC and which the BSC/NCIPC unanimously voted
to have CDC adopt, and CDC's response to observations outlined in the
OWG Report; and (4) an Overview of Community Engagement and Public
Comment Opportunities, which describes key themes that emerged about
stakeholders' values and preferences regarding pain management, as well
as CDC's response to input obtained from these efforts. The GRADE
tables include clinical evidence review ratings of the evidence for the
key clinical questions. The OWG Report describes the workgroup's
findings and observations about the initial draft clinical practice
guideline as presented to the BSC/NCIPC at a public meeting on July 16,
2021. The OWG, comprising three BSC/NCIPC members in accordance with
federal advisory committee policy, as well as patients with pain,
caregivers, and family members of patients with pain, and clinicians
and subject matter experts with a variety of relevant pain management
expertise, was designed to provide independent, broad, external,
transparent input to the BSC/NCIPC on the diverse and complex issues
addressed in the clinical practice guideline. OWG meetings were
coordinated by an NCIPC subject matter expert who served as the
Designated Federal Official. CDC's response to the OWG Report reflects
and describes how CDC incorporated OWG observations and comments in the
revised draft of the clinical practice guideline. The Overview of
Community Engagement and Public Comment Opportunities document provides
a summary of efforts implemented throughout the clinical practice
guideline update process to better understand the lived experiences and
perspectives of community members that we serve and to ensure
additional input from patients, caregivers, clinicians, and the public.
CDC's response to the themes and findings that emerged throughout the
community engagement and public comment opportunities describes how CDC
carefully considered and incorporated diverse perspectives and input
from multiple sources and stakeholders into the clinical practice
guideline.
Dated: February 7, 2022.
Angela K. Oliver,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2022-02802 Filed 2-9-22; 8:45 am]
BILLING CODE 4163-18-P
